38 Osteogenesis Imperfecta Clinical Trials in Birmingham, AL (2026)

Q: How do I join a clinical trial in Birmingham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in Birmingham

NCT02418442Recruiting

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARR...

Birmingham, AL20,000 participantsDuke University

View Study Details

NCT02474160Recruiting

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scie...

Birmingham, AL5,000 participantsNational Cancer Institute LAO

View Study Details

NCT07412002Recruiting

Quality of End-of-Life Care for Children With Cancer

This study examines the role of access to care, patient/family interactions with the healthcare system, and stress in explaining variations in quality of end of life care. The data collected from this...

Birmingham, AL2,425 participantsChildren's Oncology Group

View Study Details

NCT05550298Recruiting

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transpl...

Birmingham, AL2,000 participantsArkansas Children's Hospital Research Institute

View Study Details

NCT05564390Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical tria...

Birmingham, ALPHASE22,000 participantsNational Cancer Institute (NCI)

View Study Details

NCT04692493Recruiting

RA-PRO PRAGMATIC TRIAL

The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medicatio...

Birmingham, ALPHASE3924 participantsUniversity of Alabama at Birmingham

View Study Details

NCT07278375Recruiting

Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome

The goal of this observational study is to learn how two medicines used in routine care-buprenorphine and morphine-affect recovery in newborns (≥36 weeks' gestation) with Neonatal Opioid Withdrawal Sy...

Birmingham, AL796 participantsHELP for NOWS Consortium

View Study Details

NCT06852222Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukem...

Birmingham, ALPHASE3600 participantsJanssen Research & Development, LLC

View Study Details

NCT07022678Recruiting

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a ...

Birmingham, ALPHASE3556 participantsChildren's Oncology Group

View Study Details

NCT05208047Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two...

Birmingham, ALPHASE3482 participantsCogent Biosciences, Inc.

View Study Details

NCT05429632Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial....

Birmingham, ALPHASE3366 participantsPriothera SAS

View Study Details

NCT05554406Recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with...

Birmingham, ALPHASE2335 participantsNational Cancer Institute (NCI)

View Study Details

NCT06423911Recruiting

Study of Olverembatinib (HQP1351) in Patients With CP-CML

A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)...

Birmingham, ALPHASE3333 participantsAscentage Pharma Group Inc.

View Study Details

NCT06163430Recruiting

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with pr...

Birmingham, ALPHASE1330 participantsTerns, Inc.

View Study Details

NCT03816345Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, an...

Birmingham, ALPHASE1300 participantsNational Cancer Institute (NCI)

View Study Details

NCT02074839Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mu...

Birmingham, ALPHASE1291 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT06465199Recruiting

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Foo...

Birmingham, ALPHASE1265 participantsMilton S. Hershey Medical Center

View Study Details

NCT04260022Recruiting

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic pha...

Birmingham, ALPHASE1242 participantsAscentage Pharma Group Inc.

View Study Details

NCT03850574Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

Birmingham, ALPHASE1240 participantsAptose Biosciences Inc.

View Study Details

NCT06104280Recruiting

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medic...

Birmingham, AL200 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06593093Recruiting

A Bundled Intervention

Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment ...

Birmingham, ALPHASE1190 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06917911Recruiting

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with cor...

Birmingham, ALPHASE2162 participantsNational Cancer Institute (NCI)

View Study Details

NCT07485335Recruiting

A Bundled Intervention to End Opioid Overdoses

Birmingham, ALPHASE4160 participantsUniversity of Alabama at Birmingham

View Study Details

NCT04588922Recruiting

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation grou...

Birmingham, ALPHASE1160 participantsSellas Life Sciences Group

View Study Details

NCT06655246Recruiting

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) ...

Birmingham, ALPHASE1157 participantsKura Oncology, Inc.

View Study Details

NCT06317649Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit...

Birmingham, ALPHASE2147 participantsNational Cancer Institute (NCI)

View Study Details

NCT06824168Recruiting

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem...

Birmingham, ALPHASE2130 participantsDaiichi Sankyo

View Study Details

NCT06832007Recruiting

The Effect of Light Intervention on Recovery in Individuals With Opioid Use Disorder (OUD)

Opioid use disorder (OUD) is a chronic relapsing disorder and is well-known for its high-risk rate of overdoses and death. In OUD, sleep and circadian disruptions are highly prevalent, interfere with ...

Birmingham, ALNA105 participantsUniversity of Alabama at Birmingham

View Study Details

NCT05711667Recruiting

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transpl...

Birmingham, ALPHASE3105 participantsChildren's Oncology Group

View Study Details

NCT06205121Recruiting

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01...

Birmingham, ALPHASE296 participantsMolecure S.A.

View Study Details

NCT05143996Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)...

Birmingham, ALPHASE160 participantsCullinan Therapeutics Inc.

View Study Details

NCT06533098Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT)....

Birmingham, ALPHASE350 participantsJanssen Research & Development, LLC

View Study Details

NCT07201558Recruiting

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE....

Birmingham, ALPHASE148 participantsAstraZeneca

View Study Details

NCT07012044Recruiting

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of impr...

Birmingham, ALPHASE147 participantsNational Cancer Institute (NCI)

View Study Details

NCT06034275Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ h...

Birmingham, ALPHASE136 participantsVincerx Pharma, Inc.

View Study Details

NCT06247787Recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic sy...

Birmingham, ALPHASE136 participantsChildren's Oncology Group

View Study Details

NCT07044544Recruiting

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances wit...

Birmingham, ALPHASE120 participantsUniversity of Alabama at Birmingham

View Study Details

NCT07131696Recruiting

The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage

The significance of developing a safe and effective therapy for aneurysmal subarachnoid hemorrhage (aSAH) patients suffering cerebral vasospasm (CVS) cannot be overstated. Vasospasm - a clamping down ...

Birmingham, ALNA10 participantsMarshall Holland

View Study Details

About Osteogenesis Imperfecta Clinical Trials in Birmingham

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 38 osteogenesis imperfecta clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 39,404 participants. Research is being sponsored by Duke University, National Cancer Institute LAO, Children's Oncology Group and 20 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Birmingham — FAQ

Are there osteogenesis imperfecta clinical trials in Birmingham?

Yes, there are 38 osteogenesis imperfecta clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 38 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated October 15, 2026 from ClinicalTrials.gov